Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Busch Off to Shire, Moeller Up In Bayer R&D Consolidation; Xofigo Trial Turns Up Safety Issue

Executive Summary

Bayer is combining its research and development organization in one unit. Discovery head Andreas Busch is leaving to join Shire while development head Joerg Moeller takes overall control. Meanwhile, Xofigo was linked to more fractures and deaths than the control arm in a prostate cancer trial.

You may also be interested in...



Appointments: EMD Serono, Cellectis, Shire, Bayer, Biogen, Horizon, Alligator, Faron, Ironwood, Vectura

The latest biopharma industry appointments include R&D leadership appointments at Shire, Bayer, Alligator and Horizon Pharma, new chief medical officers for Shire and Alligator, and a new chief commercial officer for Faron Pharmaceuticals. Meanwhile, Biogen has brought in a new chief information officer.

Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases

The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.

Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel